“A recently presented poster session from RAD 2023 evaluated a gene expression based molecular test’s differential diagnosis of psoriasis and eczema.
The first evening of the 2023 Revolutionizing Atopic Dermatitis conference began with a poster reception, unveiling numerous new abstracts for viewing and discussion. From the group of accepted posters came, “Gene expression based molecular test proves clinical validity as diagnostic aid for the differential diagnosis of psoriasis and eczema in formalin fixed and paraffin embedded tissue,” from Fischer et al.
The study investigators sought to develop a real-time based molecular classifier (MC) to distinguish psoriasis from atopic eczema in FFPE-fixed skin samples for diagnostic measures and to evaluate the potential of minimally invasive microbiopsies and non-invasive tape strips for molecular diagnosis. Developing an MC capable of distinguishing psoriasis from atopic eczema was important to the investigators, as they noted that highly specific and efficient drugs have been recently developed to treat non-communicable chronic inflammatory skin diseases (ncISD). Due to these drugs’ specificity, they require precise diagnostics to attribute the most efficient treatment for each patient. “
Full article by Kaitlyn Bader, Editor Dermatology Times: